Cara stockholders approve all six merger proposals with Tvardi; Tvardi posts $29.4M net loss

Tvardi Therapeutics, Inc.

All proposals passed: stock issuance for merger (2,088,293 for), equity plan, ESPP, reverse split (1:2-1:4), authorized shares increase to 150M, and advisory compensation.
Reverse stock split ratio between 1-for-2 and 1-for-4 to be mutually agreed by Cara and Tvardi boards before merger.
Tvardi audited 2024: net loss $29.4M (vs $17.3M in 2023), cash $31.6M, with going concern qualification.
Tvardi's lead candidate TTI-101 in Phase 2 for idiopathic pulmonary fibrosis and hepatocellular carcinoma.
Merger completion subject to customary closing conditions including Cara net cash of at least $18M at closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.